Similarly, it has been shown that increased expression of TGFβ1 and SMAD3, the downstream of TGFβ1, was associated with shorter PFS or OS in patients with SCLC who were treated with immune checkpoint inhibitors in the present study. The gene discussed is TGFB1; the disease is small cell lung carcinoma.